ABBV Research
AbbVie Inc.
3.21%
Forward yield
$6.920 / yr per share
Yield percentile (5y)
P 33
3.0% (P10)3.5% (med)3.9% (P90)
Quality score
89/100
Strong · Moderate payout risk
Annual / share
$6.920
Quarterly · next ex-date 07-15 (39d)
vs 5y P90 reference
+21%
$215.42 vs $170.04 (5y P90 price)
Refreshed 2026-06-06Data coverage High — 14y history
01Fundamentals
ABBV offers a compelling 12.48% 5Y dividend growth rate and a strong 14-year dividend streak, supported by a safe 66.8% effective payout ratio. While the 2.9964% dividend yield is below the current risk-free rate and the reported 325.98% GAAP payout ratio warrants attention, the company's strong free cash flow coverage and high payout safety score of 20.0/20 indicate long-term dividend sustainability. Buy for income growth and reliability.
Bull caseThe company boasts an excellent dividend track record with 14 consecutive years of increases and a robust 12.48% 5Y dividend growth rate, underpinned by a highly safe 66.8% effective payout ratio (payout_safety 20.0/20).
Bear caseThe 2.9964% dividend yield is below the current risk-free rate, and the reported GAAP payout ratio of 325.98% indicates significant non-cash expenses or one-time items affecting statutory earnings, despite strong free cash flow of $17,816,000,000.
02Risk & quality
| Payout ratio | Moderate · 66.8% |
| Overall quality score | 89 / 100 · Strong |
Score breakdown — five dimensions, each /2020 + 20 + 18 + 8 + 10 = 89
20.0/20
Consistency
20.0/20
Payout safety
17.6/20
Moat
↓
8.4/20
Growth rate
10.0/20
Balance sheet
- Consistency 20.0/20 — ABBV has paid for 14 consecutive years — past the 10-year cap on this dimension, so it scores 20/20. Streaks under 25 don't yet qualify as Dividend Aristocrat tier, but represent a meaningful uninterrupted history.
- Payout safety 20.0/20 — ABBV pays out 66.8% of free cash flow as dividends — still inside the safe band, with some headroom before reaching 80%, the level commonly flagged as strained. Manageable as long as earnings hold up.
- Moat 17.6/20 — Scores how protected ABBV's earnings stream is from competition. Operating in Healthcare, ABBV benefits from the kind of brand pricing power, regulatory position, or scale that lets margins hold up through economic cycles. Cyclical or commodity-driven sectors typically score in the single digits here.
- Growth rate 8.4/20 — ABBV's dividend grew about 12.5% per year over 5 years — solid by absolute standards, but a notch below the 15-20% pace seen at growth-oriented dividend payers (think SCHD constituents). Familiar pattern for established staples already paying out most of what they earn — the runway for further hikes naturally narrows once payout ratios climb.
- Balance sheet 10.0/20 — A composite of return-on-equity and inverse leverage. ABBV's ROE leaves this dimension in the middle of the pack — neither flagged for weakness nor in the financial-flexibility tier of top-scoring names.
03Price reference
$10,000at current price →$321/ yr in dividends
Math: 3.21% forward yield. Historical 5y DGR is 12.5%/yr — past growth does not guarantee future results.
Below are statistical price references from the last 5 years of trading, anchored to historical drawdown events. They describe where the price has been — not where it should be.
$106.48
$170.04
$215.42
5y P10
5y P90
Now
| Current price | $215.42 |
| 5y P90 reference (high-yield 10% tail) | $170.04 — 21.1% lower |
| 5y P10 reference (low-yield 10% tail) | $106.48 — 50.6% lower |
| 5y max observed yield (at P10 price) | 4.7% |
| Annual dividend (frozen forward) | $6.920 / share · 3.21% yield |
Historical anchor · 2018 Q4 Crash
Low $56.53 · drawdown 1431 days · yield reached 6.3%
Fed tightening + US-China trade war fears, S&P dropped ~20% in Q4
Important — this is reference data, not investment advice.
Quality scores, percentiles, and price references are statistical summaries of historical data computed by our research methodology from public market data, refreshed daily. They do not constitute a buy / sell / hold recommendation, do not account for your personal financial situation, tax bracket, or goals, and past performance does not predict future results. Consult a registered investment advisor before making investment decisions. divcalc.io is not a registered investment advisor.
Quality scores, percentiles, and price references are statistical summaries of historical data computed by our research methodology from public market data, refreshed daily. They do not constitute a buy / sell / hold recommendation, do not account for your personal financial situation, tax bracket, or goals, and past performance does not predict future results. Consult a registered investment advisor before making investment decisions. divcalc.io is not a registered investment advisor.